SCHEMBL6715548

SCHEMBL6715548

COc1ccc(NCCc2c3n(c4ccccc24)CCNCC3)cc1

nearest known ligand 0.49

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 7/20 0.49
HTR2C P28335 7/20 0.49
DRD2 P14416 2/20 0.42
DRD3 P35462 2/20 0.42
HTR6 P50406 3/20 0.42
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MAPT P10636 4/20 0.39
GAA P10253 2/20 0.39
MTNR1A P48039 2/20 0.37
MTNR1B P49286 2/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6715813 0.99 HTR2A (0.48) HTR2AHTR2CDRD2DRD3HTR6
SCHEMBL6711408 0.81 ALDH1A1 (0.48) HTR2AHTR2CRAB9AMAPTALDH1A1
SCHEMBL6715469 0.79 HTR2A (0.55) HTR2AHTR2CHTR6MAPTGAA
Hydrochloric Acid SCHEMBL6714574 0.78 HTR2A (0.54) HTR2AHTR2CHTR6MAPTGAA
SCHEMBL6718270 0.75 HTR2C (0.52) HTR2AHTR2CDRD2DRD3HTR6
SCHEMBL6711086 0.75 HTR2A (0.59) HTR2AHTR2CHTR6MTNR1AMTNR1B
SCHEMBL6712349 0.75 HTR2A (0.59) HTR2AHTR2CHTR6MAPTMTNR1A
Hydrochloric Acid SCHEMBL6718740 0.74 HTR2C (0.51) HTR2AHTR2CDRD2DRD3HTR6
SCHEMBL6711275 0.74 HTR2A (0.53) HTR2AHTR2CHTR6
SCHEMBL6715495 0.73 HTR2A (0.60) HTR2AHTR2CHTR6NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds ENNIS MICHAEL DALTON (US) 2004-10-21 US disclosed
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US disclosed
EP-1328525-A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-A]INDOLE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2003-07-23 EP disclosed
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds PHARMACIA & UPJOHN COMPANY 2002-01-03 US disclosed
WO-2001072752-A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HTR1D, HTR1A, HTR1E HTR2A 18/4885HTR2C 7/4885DRD2 21/4885
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HCRTR2, NR2C2, RCOR3 HTR2A 1403/4885HTR2C 553/4885DRD2 251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.